Fri, November 29, 2024

[ Fri, Nov 29th 2024 ]: Thomas Matters

ChatGPT turns two: how has it impacted markets?

[ Fri, Nov 29th 2024 ]: Thomas Matters

Here's how I'm investing in dividend shares to aim for long-term wealth

[ Fri, Nov 29th 2024 ]: Thomas Matters

Stock Market vs. CDs: Where's The Best Place to Park Your Cash?

[ Fri, Nov 29th 2024 ]: Thomas Matters

The Fed is Losing the Inflation Battle. Investors Don't Care

[ Fri, Nov 29th 2024 ]: Thomas Matters

Prediction: Nvidia Stock Will Soar in 2025. Here's Why.

[ Fri, Nov 29th 2024 ]: Thomas Matters

This Billionaire Investor Has Owned Palantir Sinc .. Its IPO. He Just Dumped Nearly His Entire Stake.

[ Fri, Nov 29th 2024 ]: Thomas Matters

Does Warren Buffett Buy Growth Stocks? These 2 Top Buffett Stocks Are Crushing the Market.

[ Fri, Nov 29th 2024 ]: Thomas Matters

Dividends Are Never a Guarantee. These 3 Stocks Made Massive Cuts to Their Payouts This Year

[ Fri, Nov 29th 2024 ]: Thomas Matters

Can I transfer a cash ISA to a stocks and shares ISA?

[ Fri, Nov 29th 2024 ]: Thomas Matters

Should You Forget C3.ai and Buy These 2 AI Stocks Instead?

[ Fri, Nov 29th 2024 ]: Thomas Matters

Investors Looking for Stability Tap South Africa in Trump Era

[ Fri, Nov 29th 2024 ]: Thomas Matters

Scotia Global Asset Management announces fee reductions and year-end distribution estimates

[ Fri, Nov 29th 2024 ]: Thomas Matters

Active momentum funds gather steam as large fund houses enter the fray

[ Fri, Nov 29th 2024 ]: Thomas Matters

5 Mistakes to Avoid While Christmas Shopping at Costco This Year

[ Fri, Nov 29th 2024 ]: Thomas Matters

The Best Warren Buffett Stock to Buy With $500 Right Now

[ Fri, Nov 29th 2024 ]: Thomas Matters

7.7 million Australians are investing in ASX shares. Why aren't you?

[ Fri, Nov 29th 2024 ]: Thomas Matters

The Globe and Mail's 2024 Robo-Adviser Guide

[ Fri, Nov 29th 2024 ]: Thomas Matters

Bullish on Tesla, Apple, Nvidia? 4 ways to invest in international stocks
Thu, November 28, 2024

[ Thu, Nov 28th 2024 ]: Thomas Matters

What Happens To Your Money When A Mutual Fund Scheme Is Closed?

[ Thu, Nov 28th 2024 ]: Thomas Matters

Embecta upgraded to Buy from Neutral at BTIG

[ Thu, Nov 28th 2024 ]: Thomas Matters

MCAN Financial: Invested in Canadian Communities

[ Thu, Nov 28th 2024 ]: Thomas Matters

Al Harper named to Rocky Mountain Chocolate Factory board of directors

[ Thu, Nov 28th 2024 ]: Thomas Matters

Ripple's XRP could rally to $2.58 following a rise in whale buying activity

[ Thu, Nov 28th 2024 ]: Thomas Matters

Analysis-Australia's Hot Jobs Market Keeps Rate Cuts Out of Reach

[ Thu, Nov 28th 2024 ]: Thomas Matters

India's Defence Sector: Investing in Aatmanirbhar Push

[ Thu, Nov 28th 2024 ]: Thomas Matters

3 Market-Beating ETFs for Large-, Mid-, and Small-Cap Exposure

[ Thu, Nov 28th 2024 ]: Thomas Matters

How to Invest in Golden Goose Pre-IPO

[ Thu, Nov 28th 2024 ]: Thomas Matters

Digital infrastructure, interconnected Grid, & af .. t attractive investment destination: Piyush Goyal

[ Thu, Nov 28th 2024 ]: Thomas Matters

Canadian Dollar catches a break from selling pressure on Wednesday

[ Thu, Nov 28th 2024 ]: Thomas Matters

Adani Green Energy Says No Talks on New Financial Commitment With TotalEnergies

[ Thu, Nov 28th 2024 ]: Thomas Matters

OFP Funding Review 2024: : Everything You Need to Know Before Signing Up

[ Thu, Nov 28th 2024 ]: Thomas Matters

BMO ETFs: All-in-One Solutions for Simplified Investing

[ Thu, Nov 28th 2024 ]: Thomas Matters

Dow Jones Industrial Average ends Wednesday lower despite tapping record bid

[ Thu, Nov 28th 2024 ]: Thomas Matters

European Stocks off Two-Week Highs as Energy Stocks Weigh

[ Thu, Nov 28th 2024 ]: Thomas Matters

49-Year-Old Makes $5,180 a Month in Dividends Wit .. t Night' Portfolio - Top 10 Stocks You Can't Miss
Wed, November 27, 2024

[ Wed, Nov 27th 2024 ]: Thomas Matters

Is Tesla a better opportunity than Indian automakers?

[ Wed, Nov 27th 2024 ]: Thomas Matters

Here's Why Momentum in Vertiv (VRT) Should Keep going

[ Wed, Nov 27th 2024 ]: Thomas Matters

Gold funds vs ETFs: Which one should investors choose now?

[ Wed, Nov 27th 2024 ]: Thomas Matters

Stock market today: S&P 500, Nasdaq slide after key Fed inflation gauge shows faltering progress

[ Wed, Nov 27th 2024 ]: Thomas Matters

Stocks slip the day before Thanksgiving as Nvidia, Dell decline: Live updates

[ Wed, Nov 27th 2024 ]: Thomas Matters

Sudarshan Chemical shares in focus after promoters sell stake via block deals

[ Wed, Nov 27th 2024 ]: Thomas Matters

Quantum Computing: I Don't Expect Big Revenues Until 2030+

[ Wed, Nov 27th 2024 ]: Thomas Matters

Consumer Spending Powers Q3 US GDP Growth to 2.8%

[ Wed, Nov 27th 2024 ]: Thomas Matters

Why Royalty Pharma (RPRX) is the Cheapest Stock to Buy on Robinhood?

[ Wed, Nov 27th 2024 ]: Thomas Matters

Consumer-Related Stocks Help Lift TSX to Record Closing High

[ Wed, Nov 27th 2024 ]: Thomas Matters

Japanese Yen and Australian Dollar News: Will Yen Break 50 on BoJ Rate Hike Signals?

[ Wed, Nov 27th 2024 ]: Thomas Matters

USD/JPY: Oversold conditions can bush the USD downwards - UOB Group

[ Wed, Nov 27th 2024 ]: Thomas Matters

Russian Central Bank Intervenes as Rouble Tumbles Past 0 to the Dollar

Is Pfizer Stock in Trouble?

One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE). Given how well Pfizer has performed in recent years due to its COVID-19 vaccine and pill (its revenue topped $100 billion in 2022),
The article from AOL discusses the challenges faced by Pfizer Inc. as its stock has experienced a significant decline, dropping by 30% in the past year. This downturn is attributed to several factors including the waning demand for its COVID-19 vaccine and treatment, Comirnaty and Paxlovid, as the global health crisis transitions into an endemic phase. Additionally, Pfizer is dealing with patent expirations, increased competition from generic drugs, and a broader market shift away from pharmaceutical stocks. The company's efforts to diversify its portfolio through acquisitions and new product development are highlighted, but these initiatives have not yet offset the revenue loss from its blockbuster drugs. The article also touches on the broader implications for investors, suggesting that while Pfizer faces immediate headwinds, its long-term strategy might still hold promise if new products gain traction.

Read the Full AOL Article at [ https://www.aol.com/pfizer-stock-trouble-111700534.html ]